Nicholas Lydon
#56,529
Most Influential Person Now
British biochemist
Nicholas Lydon's AcademicInfluence.com Rankings
Nicholas Lydonbiology Degrees
Biology
#6191
World Rank
#8855
Historical Rank
#2021
USA Rank
Biochemistry
#938
World Rank
#1047
Historical Rank
#240
USA Rank
Download Badge
Biology
Why Is Nicholas Lydon Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia , which converted a fatal cancer into a manageable chronic condition.
Nicholas Lydon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) (5035)
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells (1996) (3664)
- Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. (2000) (1363)
- Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. (1996) (1124)
- Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. (2000) (889)
- The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. (1997) (677)
- CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. (1997) (579)
- Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. (1994) (513)
- Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. (1997) (336)
- Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. (1995) (260)
- The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. (1992) (247)
- Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α (*) (1995) (217)
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives (1997) (208)
- Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). (1998) (196)
- Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. (1997) (189)
- The structure-based design of ATP-site directed protein kinase inhibitors. (1999) (146)
- A precision therapy against cancers driven by KIT/PDGFRA mutations (2017) (137)
- 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. (1996) (127)
- Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors (1996) (120)
- 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. (1994) (101)
- Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. (1990) (88)
- Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. (1994) (73)
- Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC) (1996) (73)
- Lessons learned from the development of imatinib. (2004) (69)
- Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411 (1995) (68)
- [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. (1995) (65)
- Expression and partial characterization of rat protein kinase C‐δ and protein kinase C‐ξ in insect cells using recombinant baculovirus (1992) (62)
- Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives. (1997) (52)
- Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. (1997) (51)
- Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. (1991) (50)
- Cdc2-mediated modulation of pp60c-src activity. (1994) (46)
- Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. (1992) (42)
- Immunochemical mapping of alpha-2 interferon. (1985) (41)
- Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity. (1992) (40)
- Recent advances in protein tyrosine kinase inhibitors (1995) (34)
- Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors. (1992) (27)
- Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. (1992) (25)
- Paeciloquinones A, B, C, D, E and F: new potent inhibitors of protein tyrosine kinases produced by Paecilomyces carneus. I. Taxonomy, fermentation, isolation and biological activity. (1995) (24)
- Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src (1999) (24)
- A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo (1998) (23)
- Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. (1997) (22)
- Attacking cancer at its foundation (2009) (22)
- Inhibition of epidermal growth factor-mediated ERK1/2 activation by in situ electroporation of nonpermeant [(alkylamino)methyl]acrylophenone derivatives. (1998) (19)
- An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase. (1990) (15)
- Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus. (1992) (11)
- Phenylamino‐Pyrimidine (PAP)‐Derivatives: A New Class of Potent and Highly Selective PDGF‐Receptor Autophosphorylation Inhibitors. (1996) (11)
- Electroporation of cultured adult rat hepatocytes with the c-myc gene potentiates DNA synthesis in response to epidermal growth factor. (1988) (10)
- Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase (2001) (8)
- A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo. Int. J. Cancer, 76, 154–163 (1998) (1999) (5)
- Hepatitis B virus polymerase gene: expression of the long open reading frame using the baculovirus expression system. (1992) (4)
- Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis. (1999) (3)
- Activation of adenylate cyclase in bovine corpus-luteum membranes by human choriogonadotropin, guanine nucleotides and NaF. (1981) (2)
- A strategy for screening anti‐tumor drugs utilizing oncogenes encoded in retroviral vectors (1996) (2)
- Phenylamino-pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC) (1996) (2)
- Selective Killing of BCR-ABL Positive Cells with a Specific Inhibitor of the ABL Tyrosine Kinase (1996) (2)
- The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors (1999) (2)
- The effect of dimethyl 3,3'-dithiobispropionimidate on the adenylate cyclase activity of bovine corpus luteum; stimulation of particulate enzyme activity and the stabilization of activity to dispersion in detergent [proceedings]. (1980) (1)
- The development of Imatinib and its impact on precision medicine (2018) (0)
- Author errata. (1999) (0)
- Targeting the Human Kinome: a Rich Source of Targets for Cancer Therapy (2014) (0)
- Hormonal activation of bovine luteal adenylate cyclase [proceedings]. (1979) (0)
- monoclonal antibodies against the interferon a2 and hybridomas producing such antibodies (1984) (0)
- Applied Biological Sciences. In the articles “4,5-Dianilinoph- thalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity” by Elisabeth Buchdunger, (1998) (0)
- N TA RY Attacking cancer at its foundation (2009) (0)
- Activation of bovine luteal adenylate cyclase by human choriogonadotropin in vitro: persistence of the activated state following preactivation and washing [proceedings]. (1980) (0)
- Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs). (2023) (0)
- Purification and biochemical characterization of non-myristoylated recombinant pp 6 Oc-src kinase (2005) (0)
This paper list is powered by the following services:
Other Resources About Nicholas Lydon
What Schools Are Affiliated With Nicholas Lydon?
Nicholas Lydon is affiliated with the following schools:
